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In healthcare facilities, transmission of ID-MRSA from
a HCW to a patient has been postulated. In an earlier
report, a HCWwas colonized with MRSA after treatment with
cephalexin. Exposure to the antibiotic was the purported
inducer of phenotypic resistance. Until recently, there have
been no prior epidemiological reports of ID-MRSA in the non-
healthcare setting. A prospective epidemiologic surveillance
study identiﬁed ID MRSA in a cohort of healthy university
students. The potential impact of ID-MRSA colonization on
CA-MRSA colonization and subsequent development of skin
and soft tissue infections or invasive disease is not known.
As in the hospital setting, ID-MRSA colonization may serve
as a reservoir, thereby promoting cross-transmission within
a household, dormitory, athletic team or social unit. Colo-
nized individuals may theoretically cross transmit ID-MRSA
isolates to close contacts. Additionally, ID-MRSA colonization
or transmission may result in MRSA phenotypic conversion if
the appropriate selective antibiotic pressure is applied. Fur-
thermore, individuals persistently colonized with ID-MRSA
may play an important role in households with high rates
of CA-MRSA infections. Further studies are needed to better
deﬁne both mechanisms of resistance and the epidemiologic
signiﬁcance of ID-MRSA.
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ST8-MRSA-IV (USA300), ST80-MRSA-IV (European clone),
ST59-MRSA-IV (Taiwan clone) and in Australia ST93-MRSA-
IV (Queensland clone) and ST30-MRSA-IV (Oceania clone)
are all PVL positive. Data from Australia where CA-MRSA
has been described since the late 1980’s show that disease
severity and demographics vary widely between PVL positive
and negative clones.
Demonstrating the actual role of PVL in disease has been
controversial. Mouse and rat animal models using PVL pos-
itive and negative clones or PVL deleted mutants have
provided some support for a role in muscle damage, skin
abscess and lung necrosis but there are studies that fail
to show any association of PVL with pathogenesis of CA-
MRSA disease. In contrast rabbit models have demonstrated
a role in lung necrosis, dermatonecrosis and osteomyelitis
- a reﬂection of the greater sensitivity of rabbit polymor-
phonuclear (PMN) leucocytes to PVL than murine PMNs.
As with most biological systems one single factor is rarely
the explanation for a complex disease. Other virulence
factors have been described for CA-MRSA including core
genomic factors such as alpha haemolysin, secreted pro-
teases, phenol-soluble modulins (PSMs), increased expres-
sion of the accessory gene regulator (agr) and especially for
USA300 the possession of the arginine catabolic mobile ele-
ment (ACME) that has a role in pH homeostasis, ﬁtness and
possibly transmission. More recently PSMs that are associ-
ated with the SCCmec have been described.
Conclusion: PVL is not necessarily a driver of the CA-
MRSA epidemics being seen worldwide but is more likely a
determinant of signiﬁcant skin and soft tissue infection with
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bscess formation as well as more severe disease such as
ecrotising pneumonia, necrotising fasciitis and osteomyeli-
is.
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Driven largely by public and hence political pressure,
he NHS has made good progress in reducing MRSA bacter-
emia. By the end of June 2009, they had fallen to 26%
f 2003-04 levels in England and Wales. Little data how-
ver, is available on background MRSA colonisation rates or
ther types of infection although HAI audits suggest MRSA
s still the dominant cause of postoperative wound infec-
ion. Signiﬁant resource is now being invested in universal
dmission screening and early signs are that this is being
uccessful with signigicant reduction in colonization rate
t admission, overall burden on isolations rooms, clincially
iagnosed infections and laboratory clinical isolates. The
ittle evidence available suggests that the public is happy
ith screening programmes. Nevertheless, signiﬁcant con-
erns remain at public health level about the use of these
esources for MRSA screening and at an ethical level about
he enforced isolations of patients with possible detrimental
ffects on quality of care.
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RSA epidemiology and Control in Developing Countries
. Rosenthal
International Nosocomial Infection Control Consortium
INICC), Buenos Aires, Argentina
International infection control consortium (INICC)
eported data from January 2003 through December 2008
n 173 ICUs in Latin America, Asia, Africa, and Europe.
uring the 6-year study, using CDC NNIS/NHSN deﬁnitions
or device-associated healthcare-associated infection, we
ollected prospective data from 155,358 patients hospital-
zed in the consortium’s hospital ICUs for an aggregate of
23,624 days.
Although device utilization in the developing countries’
CUs was remarkably similar to that reported from U.S.
CUs in the CDC’s NHSN, rates of device-associated noso-
omial infection were markedly higher in the ICUs of the
NICC hospitals: the pooled rate of CVC-associated BSI in
he INICC ICUs, 7.6 per 1000 CVC days, is nearly three-
old higher than the 2.0 per 1000 CVC-days reported from
omparable U.S. ICUs, and the overall rate of ventilator-
ssociated pneumonia (VAP) was also far higher, 13.6 vs
.3 per 1000 ventilator-days, as was the rate of catheter-
ssociated urinary tract infection (CAUTI), 6.3 vs. 3.3 per
000 catheter-days.
